Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Cobimetinib as Monotherapy and in Combination with Venetoclax with or without Atezolizumab in Patients with RRMM

Conference Correspondent  - ASH Highlights

More than 50% of patients with relapsed/refractory multiple myeloma (RRMM) exhibit mitogen-activated protein kinase (MAPK) pathway mutations. Whereas MAPK kinase (MEK) inhibitors alone have shown modest activity in RRMM, combining these agents with a B-cell lymphoma 2 (BCL2) inhibitor with or without a programmed death-ligand 1 (PD-L1) inhibitor could increase efficacy by augmenting both apoptosis and the antitumor immune response. A phase 1b/2 study of single-agent cobimetinib (C; a MEK inhibitor) or C + venetoclax (V; a BCL2 inhibitor), with or without atezolizumab (A; a PD-L1 inhibitor), was conducted in patients with RRMM.

Enrollment criteria included RRMM and 3 to 5 prior therapies, including a proteasome inhibitor and an immunomodulatory drug. The safety of C+V and C+V+A, respectively, were evaluated in safety run-in (SRI) cohorts 1 and 2. Randomization was then performed 1:2:2 to cobimetinib 60 mg orally daily on days 1 through 21 (Arm A); cobimetinib 40 mg orally daily on days 1 through 21 and venetoclax 800 mg orally daily on days 1 through 28 (SRI 1, Arm B); and atezolizumab 840 mg intravenously on days 1 and 15 (SRI 2, Arm C) in 28-day cycles. Pharmacokinetic analyses and exploratory biomarker assessments were performed.

A total of 49 patients were enrolled (Arm A, n = 6; Arm B, n = 22; Arm C, n = 21). The median age was 65 years; 63% of patients were male, 94% had Eastern Cooperative Oncology Group performance status 0 to 1, and 47% had International Staging System stage II/III disease. Patients received a median of 4 prior lines of therapy (prior autologous stem-cell transplant, 43%; prior daratumumab, 41%). High-risk cytogenetics, defined as del(17p), t(4;14), t(14;16), were present in 24% of patients; 20% were t(11;14) positive; 51% had RAS mutations (KRAS, NRAS, BRAF, NF-1); and 31% had high PD-L1 expression.

The most common adverse events (AEs; any grade) were as follows: diarrhea (cobimetinib, 33%; C+V, 82%; C+V+A, 91%), nausea (cobimetinib, 17%; C+V, 50%; C+V+A, 67%), anemia (cobimetinib, 17%; C+V, 46%; C+V+A, 57%), neutropenia (cobimetinib, 0%; C+V, 32%; C+V+A, 57%), thrombocytopenia (cobimetinib, 0; C+V, 27%; C+V+A, 33%), blood creatine phosphokinase increase (cobimetinib, 17%; C+V, 32%; C+V+A, 24%), and rash (cobimetinib, 50%; C+V, 14%; C+V+A, 33%). The most common grade 3/4 AEs were neutropenia (cobimetinib, 0%; C+V, 14%; C+V+A, 38%), anemia (cobimetinib, 0%; C+V, 23%; C+V+A, 24%), thrombocytopenia (cobimetinib, 0%; C+V, 18%; C+V+A, 24%), and pneumonia (cobimetinib, 0%; C+V, 18%; C+V+A, 14%). Pneumonia was the most common serious AE (cobimetinib, 0%; C+V, 23%; C+V+A, 14%). Tumor lysis syndrome was reported in 2 patients. AEs leading to treatment discontinuation occurred in 17%, 18%, and 14% of patients receiving cobimetinib, C+V, and C+V+A, respectively. Twenty-seven deaths (55%) occurred at a median follow-up of 13.4 months (cobimetinib, 4 [67%]; C+V, 14 [64%]; C+V+A, 9 [43%]), with the leading cause being progressive disease (cobimetinib, 2 [50%]; C+V, 11 [79%]; C+V+A, 7 [78%]). Deaths, resulting from pneumonia in 1 patient (C+V) and general physical health deterioration in 1 patient (C+V+A), were considered treatment related.

Median overall survival was 12.9 months, 12.4 months, and 22.0 months with cobimetinib, C+V, and C+V+A, respectively. The overall response rate was 0% (0/6) for cobimetinib, 27% (6/22) for C+V, and 29% (6/21) for C+V+A. Higher response rates were observed with C+V and C+V+A among t(11;14) versus non-t(11;14) patients (100% [5/5] and 50% [2/4], respectively). Median duration of response was 11.5 months and 5.1 months for C+V and C+V+A, respectively. Four patients remain on treatment; 3 are t(11;14) positive and 1 is t(11;14) negative and RAS wild-type but BCL2/BCL2L1 (BCL-X) high (log2 fold change ≥2.3). No clinically relevant drug–drug interactions were observed.

Preliminary results from this phase 1b/2 study indicate that cobimetinib, C+V, and C+V+A are tolerable in heavily pretreated patients with RRMM. Moderate efficacy overall and higher efficacy for t(11;14) patients was demonstrated, thereby suggesting that biomarkers should be considered for future development of C+V in multiple myeloma.


Reference

Abstract 295. ASH 2020. December 5, 2020. Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib As a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed/Refractory Multiple Myeloma.

Related Items
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Leukemia, Novel Pharmaceuticals
Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Myelofibrosis, Novel Pharmaceuticals
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, CAR T-Cell Therapy, Lymphoma
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Clinical Trials, Lymphoma
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Graft-versus-Host-Disease
Pevonedistat plus Azacitidine Improves Outcomes versus Azacitidine Monotherapy in High-Risk MDS
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Myelodysplastic Syndromes
A Phase 2 Study of Isatuximab for Patients with Previously Treated AL Amyloidosis
Conference Correspondent  published on December 9, 2020 in ASH Highlights
VRD Consolidation Followed by Lenalidomide Maintenance versus Maintenance Alone in Transplant-Eligible Patients with NDMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
A Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for RRMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
Phase 2 GRIFFIN Study Update: Daratumumab + Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible NDMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.